# Boston Scientific vs Cencora: stocks compared

URL: https://funkfolio.com/compare/bsx-vs-cor

> Boston Scientific ($62.4B, P/E 18.2) and Cencora ($66.9B, P/E 19.5) compared: size, valuation, margins, debt, cash and price change.

---

## Boston Scientific vs Cencora

Boston Scientific (BSX), health care, and Cencora (COR), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Cencora is worth $66.9B on the stock market and Boston Scientific $62.4B: Cencora is valued at 7% more. Boston Scientific trades at 18.2 times earnings and Cencora at 19.5; operating margins in their latest fiscal years were 18.0% and 0.82%. Over the past year Boston Scientific's share price has moved -56.0% and Cencora's -1.30%.

### Key facts

- **Boston Scientific market value:** $62.4B
- **Cencora market value:** $66.9B
- **Boston Scientific P/E:** 18.2
- **Cencora P/E:** 19.5
- **Boston Scientific revenue:** $20.1B FY to 2025-12-31
- **Cencora revenue:** $321.3B FY to 2025-09-30
- **Superinvestors holding both:** 1

Market values as of 18 Nov 2026, 00:20 UTC.

Boston Scientific vs Cencora: every measure side by side

| Measure | Boston Scientific | Cencora |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-09-30 |
| Size |  |  |
| Market cap | $62.4B lower | $66.9B higher |
| Revenue | $20.1B lower | $321.3B higher |
| Earnings | $2.9B higher | $1.6B lower |
| Employees | 59,000 | — |
| Total assets | $43.7B lower | $76.6B higher |
| Valuation |  |  |
| P/E | 18.2 lower | 19.5 higher |
| P/S | 3.1 higher | 0.2 lower |
| P/B | 2.4 lower | 18.2 higher |
| Dividend yield | 0.00% lower | 0.67% higher |
| Profitability |  |  |
| Operating margin | 18.0% higher | 0.82% lower |
| Balance sheet |  |  |
| Net assets | $24.2B higher | $1.5B lower |
| Total liabilities | $19.2B lower | $74.8B higher |
| Total debt | $11.4B higher | $7.7B lower |
| Cash on hand | $2B lower | $4.4B higher |
| Price change |  |  |
| Today | -1.51% higher | -1.79% lower |
| 1 year | -56.0% lower | -1.30% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Boston Scientific 42.3, Cencora 96.0.

- Boston Scientific (BSX)
- Cencora (COR)

Boston Scientific and Cencora share prices over one year, rebased to 100: Boston Scientific ends at 42.3, Cencora at 96.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | BSX | COR |
| --- | --- | --- |
| Nov 28, 2025 | 99.8 | 101.1 |
| Dec 31, 2025 | 93.7 | 92.5 |
| Jan 30, 2026 | 91.9 | 98.4 |
| Feb 27, 2026 | 75.5 | 102.0 |
| Mar 31, 2026 | 61.7 | 86.1 |
| Apr 30, 2026 | 56.6 | 84.4 |
| May 29, 2026 | 47.5 | 73.8 |
| Jun 30, 2026 | 41.9 | 77.5 |
| Jul 31, 2026 | 45.9 | 85.3 |
| Aug 31, 2026 | 47.5 | 88.7 |
| Sep 30, 2026 | 42.9 | 82.3 |
| Oct 30, 2026 | 41.3 | 90.6 |
| Nov 17, 2026 | 42.3 | 96.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (1)

- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.1% / 0.2%

#### Boston Scientific only (12)

- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 2.6%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) 2.3%
- [Primecap team](https://funkfolio.com/gurus/primecap) 1.6%
- [Steven Romick](https://funkfolio.com/gurus/steven-romick) 1.2%
- [Louis Bacon](https://funkfolio.com/gurus/louis-bacon) 0.8%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.7%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.6%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 0.4%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 0.3%
- [Temasek](https://funkfolio.com/gurus/temasek) 0.3%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.3%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.1%

#### Cencora only (2)

- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.3%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.2%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Boston Scientific / Cencora). [Who owns BSX](https://funkfolio.com/stock/BSX/superinvestors) · [Who owns COR](https://funkfolio.com/stock/COR/superinvestors)

### More on Boston Scientific

- [Boston Scientific (BSX) stock page](https://funkfolio.com/stock/BSX)
- [Boston Scientific market cap](https://funkfolio.com/stock/BSX/market-cap)
- [Boston Scientific revenue](https://funkfolio.com/stock/BSX/revenue)
- [Boston Scientific P/E ratio](https://funkfolio.com/stock/BSX/pe-ratio)
- [Boston Scientific operating margin](https://funkfolio.com/stock/BSX/operating-margin)
- [Boston Scientific total debt](https://funkfolio.com/stock/BSX/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Cencora

- [Cencora (COR) stock page](https://funkfolio.com/stock/COR)
- [Cencora market cap](https://funkfolio.com/stock/COR/market-cap)
- [Cencora revenue](https://funkfolio.com/stock/COR/revenue)
- [Cencora P/E ratio](https://funkfolio.com/stock/COR/pe-ratio)
- [Cencora operating margin](https://funkfolio.com/stock/COR/operating-margin)
- [Cencora total debt](https://funkfolio.com/stock/COR/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Boston Scientific against its closest peers

- [Boston Scientific vs Cardinal Health](https://funkfolio.com/compare/bsx-vs-cah)
- [Boston Scientific vs Takeda Pharmaceutical](https://funkfolio.com/compare/bsx-vs-tak)
- [Boston Scientific vs argenx](https://funkfolio.com/compare/argx-vs-bsx)

#### Cencora against its closest peers

- [Cencora vs Takeda Pharmaceutical](https://funkfolio.com/compare/cor-vs-tak)
- [Cencora vs Cardinal Health](https://funkfolio.com/compare/cah-vs-cor)
- [Cencora vs argenx](https://funkfolio.com/compare/argx-vs-cor)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Boston Scientific or Cencora?**

By market value, Cencora is the larger: $66.9B against $62.4B for Boston Scientific. By revenue in its latest fiscal year, Cencora is the larger: $321.3B against $20.1B for Boston Scientific.

**Which has the higher P/E ratio?**

Cencora: 19.5, against 18.2 for Boston Scientific. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Boston Scientific: 18.0%, against 0.82% for Cencora. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has the higher dividend yield?**

Cencora: 0.67%, against 0.00% for Boston Scientific. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which has more debt?**

Boston Scientific: $11.4B, against $7.7B for Cencora. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Boston Scientific and Cencora?**

In their latest 13F filings, Israel Englander holds both.

### Cite this page

Funkfolio, “Boston Scientific vs Cencora”, data as of 18 November 2026. https://funkfolio.com/compare/bsx-vs-cor

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
